Apolipoprotein B or ApoB is a key protein in maintaining the structure of low-density lipoprotein (LDL) or "bad cholesterol" particles and other larger lipid particles that carry cholesterol esters and triglycerides in varying amounts and proportions through the bloodstream.
Apolipoprotein B levels
Apolipoprotein B or ApoB is the most abundant protein in atherogenic particles, the Apo-B100 isoform is part of the low density particles that include very low density (VLDL), intermediate density (IDL), low density (LDL) and lipoprotein a or Lp(a) particles, while the Apo-B100 isoform is part of the very low density particles.The Apo-B100 isoform is part of the low-density particles that include very low-density (VLDL), intermediate-density (IDL), low-density (LDL) and lipoprotein a or Lp(a) particles, while the Apo-B48 isoform is present in the larger particles, known as chylomicrons. The number of ApoB particles that enter and become trapped in the arterial wall is determined primarily by the number of ApoB particles found in the arterial lumen. ApoB-containing particles that are smaller and poorer in cholesterol (such as LDL particles) have a greater tendency to become trapped than larger VLDL-type ApoB particles.
Once retained in the artery wall, all ApoB particles are equally atherogenic. As the cholesterol content varies between different ApoB particles, triglyceride and cholesterol levels are not always accurate measures for estimating the number of ApoB particles and it is suggested that the number of ApoB particles may be higher than the number of VLDL particles.It is suggested that apoB levels may be a more accurate indicator of atherogenic risk or likelihood of lipid accumulation in the artery wall (Sniderman et al., 2019).
There are multiple factors that can influence ApoB levels, both genetic and non-genetic such as diet, lifestyle, medical conditions, medications, certain hormones, etc.
Number of observed variants
13.5 million variants
Number of risk loci
215 loci
Genes analyzed
Bibliography
O'Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016 Aug 20;388(10046):761-75.
Richardson TG, Sanderson E, Palmer TM, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis. PLoS Med. 2020 Mar 23;17(3):e1003062.
Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019 Dec 1;4(12):1287-1295.
